Developmental pharmacokinetics of moxalactam

Area of Science:

• Pharmacology
• Pediatrics
• Infectious Diseases

Background:

• Bacterial infections are a significant concern in infants and children.
• Understanding drug pharmacokinetics is crucial for effective treatment in pediatric populations.
• Moxalactam is an antibiotic used for bacterial infections.

Purpose of the Study:

• To evaluate the pharmacokinetic profile of moxalactam in pediatric patients.
• To assess moxalactam's disposition and elimination in children with non-CNS bacterial infections.
• To identify potential age-related differences in moxalactam pharmacokinetics.

Main Methods:

• Pharmacokinetic evaluation of moxalactam in 30 infants and children.
• Intravenous infusion of moxalactam at 50 mg/kg every 8 hours.
• Analysis of pharmacokinetic parameters after the first dose and during continuous therapy.

Main Results:

• Average elimination half-life was 1.59 hours, volume of distribution 0.331 L/kg, and plasma clearance 100.9 mL/min/1.73 m2.
• No significant differences in pharmacokinetic parameters were found between first-dose and steady-state values.
• Age-dependent changes in moxalactam elimination were observed in children ≤1 year old.

Conclusions:

• Moxalactam exhibits predictable pharmacokinetics in pediatric patients after single and multiple doses.
• Dosage adjustments for moxalactam may be necessary for infants ≤2 months of age due to altered elimination.
• Further research is warranted to refine moxalactam dosing strategies in neonates and young infants.